[go: up one dir, main page]

MX2019015360A - Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos. - Google Patents

Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos.

Info

Publication number
MX2019015360A
MX2019015360A MX2019015360A MX2019015360A MX2019015360A MX 2019015360 A MX2019015360 A MX 2019015360A MX 2019015360 A MX2019015360 A MX 2019015360A MX 2019015360 A MX2019015360 A MX 2019015360A MX 2019015360 A MX2019015360 A MX 2019015360A
Authority
MX
Mexico
Prior art keywords
antibody fragments
antidotes
neutralise
poison
performance process
Prior art date
Application number
MX2019015360A
Other languages
English (en)
Inventor
Alejandro González Canudas Jorge
Jacob GARCÍA UBBELOHDE Walter
Rosas Romero Gabriel
RIVERA MARTÍNEZ Vicente
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of MX2019015360A publication Critical patent/MX2019015360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Water Supply & Treatment (AREA)
  • Analytical Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere al campo de los productos de origen biológico basada en fragmentación de anticuerpos que se utilizan para inmunización pasiva para neutralizar toxinas presenten en venenos de animales ponzoñosos, específicamente se refiere a un producto biológico en donde el principio activo es una combinación de fragmentos de anticuerpos F(ab')2 y al proceso para obtenerlos con un mayor rendimiento y mejor calidad en cuanto a pureza y capacidad neutralizante de tales toxinas. Se describe su purificación a partir de plasma hiperinmune mediante salting out prescindiendo de cresol, de termocoagulación y de diálisis y aplicando técnicas de ultrafiltración con parámetros específicos para obtener fragmentos de F(ab')2 con purezas mayores a 95%.
MX2019015360A 2017-10-02 2017-10-02 Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos. MX2019015360A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2017/000115 WO2019070108A1 (es) 2017-10-02 2017-10-02 Proceso de alto rendimiento para la producción de antivenenos de fragmentos f (ab') 2 de anticuerpos

Publications (1)

Publication Number Publication Date
MX2019015360A true MX2019015360A (es) 2020-02-07

Family

ID=65994605

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015360A MX2019015360A (es) 2017-10-02 2017-10-02 Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos.

Country Status (5)

Country Link
EP (1) EP3680252A4 (es)
CO (1) CO2020001084A2 (es)
MA (1) MA49426B1 (es)
MX (1) MX2019015360A (es)
WO (1) WO2019070108A1 (es)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US4814433A (en) 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
EP0703925B1 (en) 1993-06-03 1999-08-18 Therapeutic Antibodies Inc. Production of antibody fragments
FI981717L (fi) 1998-08-07 2000-02-08 Borealis As Katalysaattorikomponentti, joka käsittää magnesiumia, titaania, halogeenia ja elektronidonorin, sen valmistus ja käyttö
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
ES2307807T3 (es) 2001-12-17 2008-12-01 Crucell Holland B.V. Produccion de fragmentos f(ab')2 en celulas de mamiferos.
CN101816789B (zh) 2010-04-08 2012-09-05 成都军区疾病预防控制中心军事医学研究所 抗蝰蛇蛇毒冻干血清及制备方法
MX367136B (es) 2012-10-18 2019-08-06 Inosan Biopharma S A Star Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
CN103864930B (zh) 2014-02-17 2016-08-10 中国人民解放军成都军区疾病预防控制中心 抗中国东亚钳蝎蝎毒F(ab’)2抗体制备及其使用方法

Also Published As

Publication number Publication date
MA49426A1 (fr) 2021-02-26
WO2019070108A1 (es) 2019-04-11
EP3680252A4 (en) 2021-04-28
EP3680252A1 (en) 2020-07-15
MA49426B1 (fr) 2022-09-30
CO2020001084A2 (es) 2020-02-18

Similar Documents

Publication Publication Date Title
WO2019224711A3 (en) Anti-cd33 antibodies, anti-cd33/anti-cd3 bispecific antibodies and uses thereof
WO2017009308A3 (en) Antibodies specific for hyperphosphorylated tau and methods of use thereof
MX2019007848A (es) Anticuerpos anti-pd-1 y usos de los mismos.
NZ774327A (en) Therapeutic antibodies and their uses
WO2016100261A3 (en) Method of treating cancer with cgamp or cgasmp
WO2010056898A3 (en) Rapid expression cloning of human monoclonal antibodies from memory b cells
ECSP077282A (es) Proceso para la concentración de anticuerpos y productos terapéuticos de los mismos
MX2013006611A (es) Tratamiento de formaciones iliticas al usar un agente quelante.
WO2017151971A3 (en) METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
MX2018009331A (es) Metodos para extraer proteinas a partir de un material a base de sangre.
WO2019217145A8 (en) Anti-dll3 antibodies and uses thereof
MY197735A (en) Pharmaceutical combinations comprising an anti-ly75 antibody
EP4530296A3 (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
PH12020500054A1 (en) Novel therapeutic enzyme fusion protein and use thereof
PE20240656A1 (es) Anticuerpos anti-cd20 y estructuras car-t
WO2016054053A3 (en) Hiv-1 antibodies and uses thereof (adcc and bispecific abs)
WO2019053613A3 (en) Combination treatment for cancer
MX2019015360A (es) Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos.
MX2016015574A (es) Composiciones esterilizadas de las proteinas ivig y kh para modular los linfocitos y tratar el virus de la hepatitis b.
WO2018190677A3 (en) METHOD OF PURIFYING ANALOGUE ANTIBODIES USING CATION EXCHANGE CHROMATOGRAPHY
EA202092675A1 (ru) Фармацевтические комбинации
EA202090581A1 (ru) Продукты слияния транстиретина и иммуноглобулина
PH12021550322A1 (en) Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof
PH12021550991A1 (en) Monoclonal antibody that specifically binds to cd20
EA202193035A1 (ru) Материалы и способы для модуляции иммунитета, опосредованного т-клетками